Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price dropped 6.7% during mid-day trading on Tuesday. The stock traded as low as C$6.30 and last traded at C$6.30. Approximately 200 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 1,956 shares. The stock had previously closed at C$6.75.
Devonian Health Group Price Performance
The stock has a market cap of C$17.52 million, a P/E ratio of -2.80 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The company’s fifty day simple moving average is C$7.68 and its 200-day simple moving average is C$9.89.
Devonian Health Group Company Profile
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
